



PROTEAMIB

**A Novel Treatment for Chronic
Pain in Osteoarthritic Horses**



Our company vision is to be a game changer in the development of sustainable veterinary products.

Our mission is to provide effective, safe and affordable solutions to keep animals healthy and well.



THE PROBLEM: UNMET NEEDS IN EQUINE HEALTH



Osteoarthritis (OA) affects 13.9% of horses and accounts for over 60% of all equine lameness. The primary symptom is persistent pain, which leads to loss of function, immobility, and a decreased quality of life. Current treatments are often inadequate and come with significant risks.

1

Limited Efficacy

Available analgesics like NSAIDs and corticosteroids provide only limited pain relief, with many horses becoming resistant to treatment.

2

Adverse Effects

Prolonged use of current drugs is associated with significant gastrointestinal, renal, and cardiorespiratory side effects.

3

Cartilage Damage

Some therapies, such as corticosteroids and certain analgesics, can be detrimental to articular cartilage

4

Competition Withdrawal

Many medications require long withdrawal periods for competition horses, impacting their careers.

PROATEMIB

Proatemib is a new product for treating chronic pain in osteoarthritic horses based on a reversible inhibitor of the ubiquitin-proteasome system. This approach has shown remarkable efficacy in blocking chronic pain in animal models at low, safe doses. Our goal is to bring this effective therapy to suffering horses who currently have limited and often risky treatment options.





THE SOLUTION: PROATEMIB A NOVEL MECHANISM FOR PAIN RELIEF

Targeted Molecular Action

- Our research shows that chronic pain is dependent on the ubiquitin-proteasome system (UPS). Proatemib is a new oral formulation containing a very low concentration of ixazomib, a reversible UPS inhibitor. It works by blocking the degradation of specific proteins that stimulate sensory neurons to send pain signals, effectively cutting off pain at the source.


Safety and Efficacy

- While ixazomib is approved at high doses for cancer treatment, our preclinical studies show that the very low concentrations in Proatemib can block pain without the severe adverse effects seen in oncology. This makes it a promising, safe, and effective therapy for long-term management of OA pain in horses.

MARKET OPPORTUNITY



- The global equine osteoarthritis therapeutics market was valued at \$1.12 billion in 2024 and is growing at a CAGR of 7.1% to reach \$2.09 billion by 2033, driven by the increasing prevalence of the disease, growing awareness among owners, advancements in regenerative medicine, and the high value of performance horses.
- With over 70% of racehorses suffering from lameness and OA affecting nearly 14% of all horses, there is a substantial need. In Sweden alone, this impacts over 49,000 horses.



COMPETITIVE ADVANTAGE



Our Competitive Edge

- Novel Mechanism of Action: First-in-class approach for veterinary pain.
- Superior Profile: Exceptional efficacy and safety compared to existing alternatives.
- Ease of Use: An oral formulation that owners can easily administer.
- No Cartilage Damage: Does not carry the risk of accelerating OA progression.

OUR EXPERIENCED TEAM



Irina Zaitseva, CEO

PhD in Medicinal Cell Biology with 30 years of experience in research, drug development, and project management.



Igor Lokot, Chief of the Board

PhD in Bio-organic Chemistry with 26 years in drug development and commercialization. Co-founder of Oasmia Pharmaceutical.



Charlotta Grånäs Folkesson, CMO

PhD in Medical Science with 30 years of experience in research, regulatory affairs, and quality assessment.

OUR NETWORK OF EXPERTS & COLLABORATORS



We are developing Proatemib in close collaboration with leading academic and industry experts to ensure scientific rigor, clinical relevance, and a strong IP position.

- Prof. Georgy Bakalkin (Uppsala University): Scientific mentor and specialist in neuropharmacology.
- Assoc. Prof. Aisha Siddiqah Ahmed (Karolinska Institutet): Expert in musculoskeletal disorders, OA pain pathways, and trial design.
- Dr. Mahmood Ahmed (MD, PhD): Clinical mentor and specialist in Orthopaedics.
- Groth & Co.: Trusted partner and expert in IP law for FTO and patent strategy.
- Royal Veterinary College, UK: Ongoing discussions with experts in equine OA for future clinical trials

Thank You!

WE REVOLUTIONIZE
TREATMENT IN VETERINARY
PHARMACEUTICALS



FarmPharma®